NICE knocks-back Janssen’s Imbruvica in mantle cell lymphoma
But recommends it for the rare cancer Waldenstrom’s macroglobulinaemia
Read More
Author: Dominic Tyer
UK CRO Quanticate doubles its footprint in India
Opens new Bangalore office to bolster its global offering
Read More
MSD launches once-daily Isentress in the UK
Will be better placed to compete head on with ViiV’s rival integrase inhibitor Tivicay
Read More
Mixed fortunes continue for Ionis rare disease drug inotersen
Meets its Phase III targets but concerns remain over its side effects profile
Read More
Astellas completes 800 million euro biotech acquisition
Belgium’s Ogeda is now a wholly-owned subsidiary of the Japanese pharma firm
Read More
